MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.
Andrew R Green,
Mohammed A Aleskandarany,
Devika Agarwal,
Somaia Elsheikh,
Christopher C Nolan,
Maria Diez-Rodriguez,
R Douglas Macmillan,
Graham R Ball,
Carlos Caldas,
Srinivasan Madhusudan,
Ian O Ellis,
Emad A Rakha
Jan 11, 2018
BACKGROUND: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic...